Russian Journal of AllergyRussian Journal of AllergyРоссийский Аллергологический Журнал1810-88302686-682XPublishing House ABV Press53610.36691/RJA536ArticlesСтатьиResearch ArticleAlvesco: new molecule in new inhalation device - new possibilities in asthma controlАльвеско: новая молекула и новое средство доставки -новые возможности контроля бронхиальной астмыIlinaN IИльинаН ИLatyshevaE AЛатышеваЕ Аealat@mail.ruInstitute of Immunology RussiaФГБУ «ГНЦ институт иммунологии» ФМБА России15042014112NO2 (2014)№2 (2014)737810032020Copyright ©; 2014, Pharmarus Print MediaCopyright ©; 2014, Фармарус Принт Медиа2014Pharmarus Print MediaФармарус Принт Медиаhttps://rusalljournal.ru/raj/article/view/536

The article presents the data about the new molecule inhaled glucocrticosteroid (iGCS) - ciclesonide in a new delivery device pMDA-HFA. A detailed analysis of the main characteristics of the drug molecules and means of their delivery was conducted according to international data. The results of observational study of the use of Alvesco in bronchial asthma patients in the real clinical practice of the Institute of Immunology are discussed.

Представлены данные о новой молекуле ингаляционного глюкокортикостероида (циклесонид) в новом средстве доставки ДАи-ГФА. Проведен подробный анализ особенностей самой молекулы препарата и средства доставки с использованием международных исследований. Приведены результаты наблюдательного исследования препарата Альвеско в реальной клинической практике у больных, обратившихся в ФГБУ «ГНЦ институт иммунологии» ФМБА России.

bronchial asthmaciclesonideAlvescopMDAHFAEverard M.L., Devadason S.G., Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 1997, v. 91, р. 624-628.Nave R., Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids. Int. J. Gen. Med. 2013, v. 6, р. 99-107.Williams L.K., Pladevall M., Xi H. et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J. Allergy Clin. Immunol. 2004, v. 114, р. 1288-1293.Leach C., Colice G.L., Luskin A. Particle size of inhaled corticosteroids: does it matter? J. Allergy Clin. Immunol. 2009, v. 124, р. 88-93.Dolovich M.A. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir. Care. 2000, v. 45, р. 597-608.Bjermer L. Targeting small airways, a step further in asthma management. Clin Respir J 2011;5:131-135.Derendorf H. Pharmacokinetic and Pharmacodynamic Properties of Inhaled Cidesonide. Journal of Clinical Pharmacology 2007;47:782-789.Nave R. et al. Metabolism of cidesonide in the upper and lower airways: review of available data. Journal of Asthma and Allergy 2008;1:11 -18.Rossi G.A. et al. Safety of inhaled corticosteroids: Room for improvement. Pulmonary Pharmacology &Therapeutics 2007;20:23-35.Mutch E. et al. The role of esterases in the metabolism of cidesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73:1657-1664.Martin R.J. Therapeutic significance of distal airway inflammation in asthma. J. Allergy Clin. Immunol. 2002, v. 109, р. 447-460.Contoli M., Bousquet J., Fabbri L.M. et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010, v. 65, р. 141-151.Bethke T.D., Drollman A., Hauns B. et al. Bioequivalence of two ciclesonide dosing regimen (4 puffs of 200 μg versus 16 puffs of 50 μg using a MDI). Eur. Respir. J. 2002, v. 20, 109 s.Leach C.L., Davidson P.J., Hasselquist B.E. et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002, v. 122, р. 510-516.Drollmann A., Nave R., Steinijans V.W. et al. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin. Pharmacokinet. 2006, v. 45, р.729-736.Gabrio B.J., Stein S.W., Velasquez D.J. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. 1999, v. 186, р. 3-12.Mutch E., Nave R., McCracken N. et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007, v. 73, р. 1657-1664.Nave R., McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J. Asthma Allergy. 2008, v. 1, р. 11-18.Christie P. Ciclesonide: a novel inhaled corticosteroid for asthma. Drugs Today (Barc). 2004, v. 40, р. 569-576.Nave R., Fisher R., McCracken. In vitro metabolism of beclo-methasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices. Respiratory Research 2007, doi:10.1186/1465-9921-8-65.Wu K. I., Blomgren A.L., Ekholm K. et al. Budesonide and ciclesonide: effect of tissue binding on pulmonary receptor binding. Drug Metab. Dispos. 2009, v. 37, р. 1421-1426.Harrison T.W., Wisniewski A., Honour J., Tattersfield A.E. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001, v. 56, р. 186-191.Nave R., Zech K., Bliesath H., Bethke T Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations. Eur. Respir. J. 2003, v. 22, р. 45.Pedersen S., Potter P., Dachev S. et al. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study. Respir. Med. 2010, v. 104, р. 1618-1628.Wilson A.M., Duong M., Pratt B. et al. Anti-inflammatory effects of once daily low dose inhaled ciclesonide in mild to moderate asthmatic patients. Allergy. 2006, v. 61, р. 537-554.Bateman E., Karpel J., Casale T et al. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest. 2006, v. 129, р. 1176-1187.O’Connor B.J., Kilfeather S., Cheung D. et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks. Eur. Respir J. 2002, v. 20 (suppl. 38): Abstract 2579.Langdon C.G., Adler M., Mehra S. et al. Once-daily ciclesonide is safe and effective in patients with persistent asthma. Respir. Med. 2005, v. 99, р. 1275-1285Chapman K.R., Patel P., D’Urzo A.D. et al. Maintenance of asthma control by once-daily ciclesonide in adults with persistent asthma. Allergy. 2005, v. 60, р. 330-337.Gelfand E.W., Georgitis J.W., Noonan M., Ruff M.E. Once-daily ciclesonide in children: efficacy and safety in asthma. J. Pediatr. 2006, v. 148, р. 377-383.Postma D.S., Sevette C., Martinat Y. et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur. Respir. J. 2001, v. 17, р. 1083-1088.Knox A., Langan J., Martinot J.B. et al. Comparison of a step-down dose of once-daily ciclesonide with a continued dose of twice-daily fluticasone propionate in maintaining control of asthma. Curr. Med. Res. Opin. 2007, v. 23, р. 2387-2394.